February 07, 2018


Levofloxacin in 5 Percent Dextrose 250mg/50mL by AuroMedics: Recall-Presence of Visible Particulate Matter

Drug
Cautionary Notice


Source:

FDA MedWatch

Issue:

AuroMedics Pharma LLC is voluntarily recalling one lot of Levofloxacin in 5% Dextrose Injection 250mg/50mL in a Single-Use flexible container NDC 55150-243-46, Lot CLF160003, Expiry date May 2018, to the hospital level. The product has been found to contain visible particulate matter tentatively identified as mold. This problem was discovered as a result of a product complaint in which the contents of one flexible bag was found to contain white particulate matter.

Use of a non-sterile injectable product could result in fatal infections in a broad array of patients.

Background:

Levofloxacin injection is indicated for the treatment of adults (≥18 years of age) with mild, moderate, and severe infections. The product can be identified as a single-use, ready-to-use flexible plastic infusion bag in a foil laminate overwrap. AuroMedics shipped the lot to wholesalers and/or hospitals nationwide September 19 through October 31, 2017.

Recommendation:

AuroMedics Pharma LLC is notifying its distributors and customers by recall letters and is arranging for return/replacement etc. of all recalled product. Consumers/distributors/retailers that have the product lot which is being recalled should immediately stop using and return to place of purchase/contact their doctor as appropriate.

Consumers with questions regarding this recall can contact AuroMedics Customer Service Monday through Friday from 9:00AM to 5:00PM EST at 888-238-7880 Option 1. If you need assistance in returning your product or have questions about the recall process, contact Inmar at 800-967-5952, Monday through Friday from 8:30 AM to 5:00 PM EST. Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product.

Healthcare professionals and patients are encouraged to report adverse events or side effects related to the use of these products to the FDA's MedWatch Safety Information and Adverse Event Reporting Program:
  • Complete and submit the report Online: www.fda.gov/MedWatch/report.htm
  • Download form or call 1 (800) 332-1088 to request a reporting form, then complete and return to the address on the pre‐addressed form, or submit by fax to 1 (800) FDA-0178.


Disclaimer:

The North American Spine Society is committed to quality patient care through promotion of patient safety and prevention of medical errors. NASS monitors a variety of government and other resources for patient safety-related notices that may be useful to our members. Information from these notices is also archived on the NASS website. This information is provided as a service for information and education only.